Neurosense Therapeutics is trading 5.5% lower at $2.90 after closing at $3.07 in the October 16 regular session; no clear company-specific catalyst was identified.
- Coverage showed no October 16 company headlines; latest prominent company news was a Nasdaq hearing set for November 10 after an appeal of a delisting determination.
- The Nasdaq Composite fell 2.12% and S&P 500 fell 1.37%; broader risk sentiment may have added pressure, but evidence does not establish a direct cause.